BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 22752912)

  • 21. Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.
    Mooney AJ; Gabbard JD; Li Z; Dlugolenski DA; Johnson SK; Tripp RA; He B; Tompkins SM
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28931689
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cross-protective efficacies of highly-pathogenic avian influenza H5N1 vaccines against a recent H5N8 virus.
    Park SJ; Si YJ; Kim J; Song MS; Kim SM; Kim EH; Kwon HI; Kim YI; Lee OJ; Shin OS; Kim CJ; Shin EC; Choi YK
    Virology; 2016 Nov; 498():36-43. PubMed ID: 27543757
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mucosal administration of raccoonpox virus expressing highly pathogenic avian H5N1 influenza neuraminidase is highly protective against H5N1 and seasonal influenza virus challenge.
    Kingstad-Bakke B; Kamlangdee A; Osorio JE
    Vaccine; 2015 Sep; 33(39):5155-62. PubMed ID: 26271828
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A two dose immunization with an inactivated reassortant H5N2 virus protects chickens against lethal challenge with homologous 2.3.2.1 clade and heterologous 2.2 clade highly pathogenic avian influenza H5N1 viruses.
    Bhat S; Sood R; Shukla S; Khandia R; Pateriya AK; Kumar N; Singh VK; Kalaiyarasu S; Kumar M; Bhatia S
    Vet Microbiol; 2018 Apr; 217():149-157. PubMed ID: 29615248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Measurement of neutralizing antibody responses against H5N1 clades in immunized mice and ferrets using pseudotypes expressing influenza hemagglutinin and neuraminidase.
    Tsai C; Caillet C; Hu H; Zhou F; Ding H; Zhang G; Zhou B; Wang S; Lu S; Buchy P; Deubel V; Vogel FR; Zhou P
    Vaccine; 2009 Nov; 27(48):6777-90. PubMed ID: 19732860
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity and protective efficacy of cold-adapted X-31 live attenuated pre-pandemic H5N1 influenza vaccines.
    Jang YH; Jung EJ; Byun YH; Lee KH; Lee EY; Lee YJ; Seong BL
    Vaccine; 2013 Jul; 31(33):3339-46. PubMed ID: 23742997
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice.
    Harada Y; Ninomiya-Mori A; Takahashi Y; Shirakura M; Kishida N; Kageyama T; Tada Y; Tashiro M; Odagiri T
    Vaccine; 2011 Oct; 29(46):8330-7. PubMed ID: 21911027
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heterosubtypic antibody response elicited with seasonal influenza vaccine correlates partial protection against highly pathogenic H5N1 virus.
    Ding H; Tsai C; Zhou F; Buchy P; Deubel V; Zhou P
    PLoS One; 2011 Mar; 6(3):e17821. PubMed ID: 21464977
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The highly conserved HA2 protein of the influenza A virus induces a cross protective immune response.
    Lee JS; Chowdhury MY; Moon HJ; Choi YK; Talactac MR; Kim JH; Park ME; Son HY; Shin KS; Kim CJ
    J Virol Methods; 2013 Dec; 194(1-2):280-8. PubMed ID: 24004822
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recombinant parainfluenza virus 5 vaccine encoding the influenza virus hemagglutinin protects against H5N1 highly pathogenic avian influenza virus infection following intranasal or intramuscular vaccination of BALB/c mice.
    Mooney AJ; Li Z; Gabbard JD; He B; Tompkins SM
    J Virol; 2013 Jan; 87(1):363-71. PubMed ID: 23077318
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Co-administration of certain DNA vaccine combinations expressing different H5N1 influenza virus antigens can be beneficial or detrimental to immune protection.
    Patel A; Gray M; Li Y; Kobasa D; Yao X; Kobinger GP
    Vaccine; 2012 Jan; 30(3):626-36. PubMed ID: 22119588
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.
    Kamal RP; Blanchfield K; Belser JA; Music N; Tzeng WP; Holiday C; Burroughs A; Sun X; Maines TR; Levine MZ; York IA
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28768855
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A cationic liposome-DNA complexes adjuvant (JVRS-100) enhances the immunogenicity and cross-protective efficacy of pre-pandemic influenza A (H5N1) vaccine in ferrets.
    Liu F; Sun X; Fairman J; Lewis DB; Katz JM; Levine M; Tumpey TM; Lu X
    Virology; 2016 May; 492():197-203. PubMed ID: 26967975
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cross-Protection by Inactivated H5 Prepandemic Vaccine Seed Strains against Diverse Goose/Guangdong Lineage H5N1 Highly Pathogenic Avian Influenza Viruses.
    Criado MF; Sá E Silva M; Lee DH; Salge CAL; Spackman E; Donis R; Wan XF; Swayne DE
    J Virol; 2020 Nov; 94(24):. PubMed ID: 32999029
    [TBL] [Abstract][Full Text] [Related]  

  • 35. H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans.
    Khurana S; Wu J; Verma N; Verma S; Raghunandan R; Manischewitz J; King LR; Kpamegan E; Pincus S; Smith G; Glenn G; Golding H
    J Virol; 2011 Nov; 85(21):10945-54. PubMed ID: 21865396
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction of Broad-Based Immunity and Protective Efficacy by Self-amplifying mRNA Vaccines Encoding Influenza Virus Hemagglutinin.
    Brazzoli M; Magini D; Bonci A; Buccato S; Giovani C; Kratzer R; Zurli V; Mangiavacchi S; Casini D; Brito LM; De Gregorio E; Mason PW; Ulmer JB; Geall AJ; Bertholet S
    J Virol; 2016 Jan; 90(1):332-44. PubMed ID: 26468547
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A single immunization with CoVaccine HT-adjuvanted H5N1 influenza virus vaccine induces protective cellular and humoral immune responses in ferrets.
    Bodewes R; Kreijtz JH; van Amerongen G; Geelhoed-Mieras MM; Verburgh RJ; Heldens JG; Bedwell J; van den Brand JM; Kuiken T; van Baalen CA; Fouchier RA; Osterhaus AD; Rimmelzwaan GF
    J Virol; 2010 Aug; 84(16):7943-52. PubMed ID: 20519384
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of American-Lineage Influenza H5N2 Reassortant Vaccine Viruses for Pandemic Preparedness.
    Chen PL; Hu AY; Lin CY; Weng TC; Lai CC; Tseng YF; Cheng MC; Chia MY; Lin WC; Yeh CT; Su IJ; Lee MS
    Viruses; 2019 Jun; 11(6):. PubMed ID: 31212631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reverse micelle-encapsulated recombinant baculovirus as an oral vaccine against H5N1 infection in mice.
    Prabakaran M; Madhan S; Prabhu N; Geng GY; New R; Kwang J
    Antiviral Res; 2010 May; 86(2):180-7. PubMed ID: 20153776
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.